Simris Group (SIMRIS) Q2 2025 earnings summary

Executive summary

• Net revenue for Q2 2025 increased by 8% to SEK 687k compared to the same quarter last year, while interim period revenue decreased by 27% year-over-year to SEK 846k.

• EBITDA loss improved by 51% in Q2 to SEK -2,980k and by 41% for the interim period to SEK -6,704k year-over-year.

• Operating result (EBIT) improved by 32% in Q2 and by 26% for the interim period compared to the previous year.

• Strategic focus remains on preclinical development of microcystin payloads for oncology, with new collaborations and technical milestones achieved.

• Legacy nutrition operations are being wound down to focus resources on biopharmaceutical development.

Financial highlights

• Q2 net revenue: SEK 687k (up 8% year-over-year); interim net revenue: SEK 846k (down 27% year-over-year).

• Q2 EBITDA: SEK -2,980k (improved 51%); interim EBITDA: SEK -6,704k (improved 41%).

• Q2 EBIT: SEK -6,693k (improved 32%); interim EBIT: SEK -13,981k (improved 26%).

• Cash flow from operating activities improved by 70% in Q2 and by 40% for the interim period year-over-year.

• Cash at period end: SEK 1,026k, down 41% year-over-year.

Outlook and guidance

• Second half of 2025 expected to be pivotal, with completion of critical preclinical experiments and ongoing strategic partnership discussions.

• Board warns current cash reserves may not cover operations through year-end; active efforts underway to secure additional funding.